The Food and Drug Administration is set to release detailed analyses of the first Covid-19 vaccine being considered for U.S. distribution, providing the foundation for Thursday’s pivotal meeting of a panel that will advise on its possible approval for emergency use.

The agency is expected Tuesday to release two separate analyses, one from its own staff scientists and one from the vaccine’s manufacturers, Pfizer Inc. and German partner BioNTech SE .

Both are likely to number in the hundreds of pages, and will document findings that show the vaccine’s effectiveness. Pfizer reports its vaccine is 95% effective at protecting against symptomatic Covid-19, and the U.K. approved its use last week.

Among other issues, the data are expected to show how the vaccine works with different age, ethnic and other demographic groups. The FDA has advised vaccine companies that these subgroup analyses will help overcome any hesitancy among Americans to be vaccinated.

A positive recommendation from the advisory panel is likely to lead to the FDA’s formally granting an emergency-use authorization of the vaccine in a matter of days.

This post first appeared on wsj.com

You May Also Like

Sean ‘Diddy’ Combs and Cassie reach settlement day after lawsuit accused him of rape

Rapper and music executive Sean Combs and the singer Cassie have reached…

Russia fires 31 missiles at Kyiv in first attack on Ukraine’s capital in 44 days

Russia fired 31 ballistic and cruise missiles at Kyiv before dawn Thursday…

Ron DeSantis shares his concerns about Trump in a private call with supporters

Florida Gov. Ron DeSantis told backers of his unsuccessful presidential bid Wednesday…

Eight dogs on way to K9 training facility die from heat-related illness after truck’s AC unit fails

At least 8 dogs being transported to a K9 training facility in…